Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study

BACKGROUND: Biliary tract cancer (BTC) is a dismal disease, even after curative intent surgery. We conducted this prospective, non-randomized phase II study to evaluate the feasibility and efficacy of cisplatin and gemcitabine as adjuvant treatment in patients with resected BTC. METHODS: Patients in...

Descripción completa

Detalles Bibliográficos
Autores principales: Siebenhüner, Alexander R., Seifert, Heike, Bachmann, Helga, Seifert, Burkhardt, Winder, Thomas, Feilchenfeldt, Jonas, Breitenstein, Stefan, Clavien, Pierre-Alain, Stupp, Roger, Knuth, Alexander, Pestalozzi, Bernhard, Samaras, Panagiotis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765636/
https://www.ncbi.nlm.nih.gov/pubmed/29325521
http://dx.doi.org/10.1186/s12885-017-3967-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765636/
https://www.ncbi.nlm.nih.gov/pubmed/29325521
http://dx.doi.org/10.1186/s12885-017-3967-0

Ejemplares similares